Articles tagged "Liver transplantation"

2020 American Transplant Congress
De Novo NAFLD Post-Liver Transplant is Defined by Altered Lipid Metabolism and Mitochondrial Dysfunction
M. Bhat¹, E. Pasini¹, M. Angeli¹, J. Allard², A. Humar¹
¹Multi-Organ Transplant, UHN, Toronto, ON, Canada, ²Division of Gastroenterology and Hepatology, UHN, Toronto, ON, Canada
*Purpose: De Novo Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 35% of liver transplant (LT) recipients transplanted for non-NAFLD indications. Non-alcoholic steatohepatitis (NASH), the…
2020 American Transplant Congress
Early Outcomes with the Liver-Kidney Safety Net
R. M. Cannon¹, D. S. Goldberg², D. E. Eckhoff¹, D. J. Anderson¹, B. J. Orandi¹, J. E. Locke¹
¹University of Alabama at Birmingham, Birmingham, AL, ²University of Miami, Miami, FL
*Purpose: A safety net policy was implemented in August 2017 giving liver alone recipients with significant renal dysfunction post-transplant priority for subsequent renal transplantation. This…
2020 American Transplant Congress
Fate of Donor-Derived Regulatory Dendritic Cells (DCreg) and Augmentation of Host Regulatory T Cells Following Their Infusion Into Prospective Living-Donor Liver Transplant Recipients
A. W. Thomson, C. Macedo, A. F. Zahorchak, X. Gu, A. Humar, F. G. Lakkis, M. A. Styn, D. M. Metes
Starzl Transplantation Institute, Pittsburgh, PA
*Purpose: Our purpose was to ascertain the fate of ex vivo-generated donor-derived DCreg and their influence on host T cells prior to transplant in a…
2020 American Transplant Congress
Liver Transplantation of Hepatitis C Viremic Donors to Hepatitis C Naive Recipients
R. K. Gilroy, F. Lopez-Verdugo, G. Harmston, S. Fujita, M. E. Boschert, I. Zendejas, E. J. Frech, A. Gagnon, R. Jones, J. Krong, S. Sell, S. Dow, L. Lindberg, M. Rodriguez-Davalos, D. Alonso
Transplant Services, Intermountain Healthcare, Murray, UT
*Purpose: This study describes outcomes, out to 3 years, at one of the first centers in the United States to begin Hepatitis C Virus (HCV)-Nucleic…
2020 American Transplant Congress
MTOR Inhibitor Management and Wound Complications in Liver Transplant Recipients Undergoing Subsequent Surgeries
K. Neuhaus, B. Eghtesad, K. Hashimoto, M. Spinner, J. Bollinger, J. Eckardt
Cleveland Clinic, Cleveland, OH
*Purpose: Class-related, concentration-dependent adverse effects associated with mTOR inhibitors (mTORi) include wound complications such as impaired wound healing, incisional hernias, hepatic artery thrombosis, and lymphocele…
2020 American Transplant Congress
Long Term Ursodeoxycholic Acid Use Does Not Alter Long Term Rejection, Biliary Complication, Mortality or Hospitalization Rates after Liver Transplantation
T. Ashraf¹, V. Mendiratta², S. Gill¹, A. Abdelwahab³, D. Moonka², S. Jafri²
¹Internal Medicine, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, ³Wayne State University, Detroit, MI
*Purpose: Endogenous bile acids are suspected to contribute to hepatobiliary injury after liver transplantation through direct cytotoxic effects. Ursodeoxycholic acid (UDCA) has been shown to…
2020 American Transplant Congress
A Three-Decade Analysis of Pancreatic Adenocarcinoma Following Liver Transplantation
O. Y. Mousa¹, J. E. Corral², K. Wijarnpreecha², R. Shah³, V. S. Louwagie⁴, M. J. Bartel⁵, B. Brahmbhatt²
¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Jacksonville, FL, ³Emory University, Atlanta, GA, ⁴Mayo Clinic Health System, Mankato, MN, ⁵Fox Chase Cancer Center, Philadelphia, PA
*Purpose: Liver transplant (LT) recipients are at risk of serious long term complications, including a higher risk of de novo malignancies compared to the general…
2020 American Transplant Congress
Normothermic Machine Perfusion of Genetically Modified Pig Livers with Human Blood
D. Detelich¹, T. M. Coe², C. G. Rickert², C. Carroll², N. Serifis², R. Matheson², I. Rosales², W. Qin³, Y. Kan³, J. Layer³, M. Youd³, W. Westlin³, S. Kimura², A. Azimzadeh², L. Yang³, J. F. Markmann²
¹Tufts Medical Center, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³eGenesis, Cambridge, MA
*Purpose: Barriers to pig-to-human liver xenotransplantation remain, including profound thrombocytopenia, coagulopathy, and rejection. We utilized ex-vivo liver xenoperfusion with human blood to study the human…
2020 American Transplant Congress
Hepaticojejunostomy versus Duct to Duct Anastomosis in Liver Transplantation: An Old Question Revisited
A. M. Elsabbagh, M. T. Shamaa, A. Al-Kurd, F. Tinney, T. Ivanics, A. Mohamed, K. Delvecchio, S. Yeddula, M. Rizzari, K. Collins, A. Yoshida, M. Abouljoud, S. Nagai
Henry Ford Hospital, Detroit, MI
*Purpose: Two surgical techniques are currently used for biliary reconstruction and each has its advantages/disadvantages. However, it is unclear if the used technique can impact…
2020 American Transplant Congress
Risk Factors Associated with Hepatic Artery Thrombosis in the Modern Era
M. Krach, A. Kernodle, P. Chiang, D. Segev, A. Massie, J. Garonzik-Wang
Johns Hopkins, Baltimore, MD
*Purpose: Historically, hepatic artery thrombosis (HAT) has been associated with certain risk factors, such as donor age, cold ischemia time, and split grafts; it is unclear…